BioSpace News Archive

Persivia, a provider of real-time bundled payment, value-based care, population health, and quality management solutions, today announced the launch of a new COVID-19 surveillance module within its Soliton™ AI engine

Clarify Medical today announced the appointment of Linda Kotcher as its Vice President of Market Access and Reimbursement, effective immediately.

PPD, Inc. (Nasdaq:PPD) has been named by IDG’s CIO as a 2020 CIO 100 Awards honoree for deploying a data-visualization platform enabling PPD to more quickly visualize targeted patient populations and investigator sites conducting clinical trials for pharmaceutical and biotech customers, helping speed the development of life-changing medicines.

Sofinnova Investments, a clinical stage biopharmaceutical investment firm, announces the addition of Jonathan Leff, M.D. to the investment team as an Executive Partner.

PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today announced its PURE® Hard Surface disinfectant (EPA Reg. No. 72977-5-73912) has been added to the U.S. EPA’s List N: Disinfectants for Use Against SARS-CoV-2 (the EPA’s expanded list of disinfectants for use against COVID-19) based on its efficacy against the Human Coronavirus.

Fund Promotes Social Distancing and Assistance for Needed Services and Products

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) today announced topline results from a clinical study evaluating the safety and pharmacokinetics of Caldolor® (ibuprofen) Injection in children ranging from birth to six months of age.

RIBOMIC Inc. , today announced that RIBOMIC has signed the license agreement with AJU PHARM CO., LTD., Korean pharmaceutical company (“AJU”), for RBM-007 licensing agreement for the indication of the exudative age-related macular degeneration in the territory of Korea and Sout

The American Healthcare Documentation Professionals Group, Inc. announced the immediate availability of a new online training program entitled, The Art of the Chart - The Basics.

GEMoaB, a biopharmaceutical company focused on the development of next-generation immunotherapies for hard-to-treat cancers, today announced that “Nature Scientific Reports” has published pre-clinical proof-of-concept data on UniCAR-modified off-the-shelf Natural Killer (NK) cells targeting GD2-expressing tumors (Mitwasi et al. 2